Systematic Financial Management LP Sells 29,345 Shares of Valeant Pharmaceuticals (VRX)

Systematic Financial Management LP cut its holdings in shares of Valeant Pharmaceuticals (NYSE:VRX) (TSE:VRX) by 35.5% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 53,215 shares of the specialty pharmaceutical company’s stock after selling 29,345 shares during the period. Systematic Financial Management LP’s holdings in Valeant Pharmaceuticals were worth $1,237,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in VRX. Fosun International Ltd acquired a new stake in shares of Valeant Pharmaceuticals during the 1st quarter worth approximately $27,705,000. Bank of Montreal Can acquired a new stake in shares of Valeant Pharmaceuticals during the 2nd quarter worth approximately $76,236,000. Moody Lynn & Lieberson LLC acquired a new stake in shares of Valeant Pharmaceuticals during the 2nd quarter worth approximately $2,760,000. Guggenheim Capital LLC boosted its position in shares of Valeant Pharmaceuticals by 49.6% during the 1st quarter. Guggenheim Capital LLC now owns 27,511 shares of the specialty pharmaceutical company’s stock worth $438,000 after acquiring an additional 9,127 shares in the last quarter. Finally, Bellevue Group AG boosted its position in shares of Valeant Pharmaceuticals by 30.0% during the 2nd quarter. Bellevue Group AG now owns 130,000 shares of the specialty pharmaceutical company’s stock worth $3,021,000 after acquiring an additional 30,000 shares in the last quarter. 46.95% of the stock is currently owned by institutional investors.

Several analysts recently issued reports on VRX shares. Cantor Fitzgerald set a $25.00 price target on shares of Valeant Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, May 14th. Jefferies Financial Group raised their target price on shares of Valeant Pharmaceuticals to $23.00 and gave the company a “buy” rating in a research report on Wednesday, May 9th. TD Securities raised their target price on shares of Valeant Pharmaceuticals from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, May 9th. Deutsche Bank raised their target price on shares of Valeant Pharmaceuticals from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, April 30th. Finally, Mizuho upgraded shares of Valeant Pharmaceuticals from a “neutral” rating to a “buy” rating in a research report on Tuesday, May 15th. Four investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $20.51.

Shares of NYSE:VRX opened at $23.40 on Monday. The firm has a market cap of $8.16 billion, a PE ratio of 6.11, a price-to-earnings-growth ratio of 0.35 and a beta of -0.38. The company has a current ratio of 1.18, a quick ratio of 0.92 and a debt-to-equity ratio of 5.59. Valeant Pharmaceuticals has a 52 week low of $10.94 and a 52 week high of $27.79.

Valeant Pharmaceuticals Company Profile

Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S.

Featured Article: Technical Analysis of Stocks and What It Means

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals (NYSE:VRX) (TSE:VRX).

Institutional Ownership by Quarter for Valeant Pharmaceuticals (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply